OS Therapies (OSTX) Convertible Debt (2023 - 2024)

OS Therapies' (OSTX) quarterly Convertible Debt came in at $1.1 million in Q2 2024, little changed on a QoQ basis from $1.1 million in Q1 2024.

OS Therapies (OSTX) Convertible Debt (2023 - 2024) Analysis & Trends

OS Therapies (OSTX) has 2 years of Convertible Debt data on file, last reported at $1.1 million in Q2 2024.

Quarterly Convertible Debt changed N/A year-over-year to $1.1 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $1.1 million (changed N/A YoY) and the FY2023 annual result came in at $150000.0, changed N/A from the prior year.
Convertible Debt steadied at $1.1 million in Q2 2024, from $1.1 million in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $1.1 million in Q2 2024 to a low of $150000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.84 Bn	131.99 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.48 Bn	78.49 Bn	3.93 Bn
3	Argenx Se	65.47 Bn	60.29 Bn	1.37 Bn
4	Moderna	60.15 Bn	55.01 Bn	52.00 Mn
5	BeOne Medicines	42.22 Bn	37.12 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.67 Bn	28.36 Bn	992.69 Mn
7	BioNTech SE	28.54 Bn	10.14 Bn	668.28 Mn
8	Insmed	27.58 Bn	26.42 Bn	358.27 Mn
9	Royalty Pharma	27.22 Bn	26.38 Bn	-
10	OS Therapies	19.85 Mn	19.85 Mn	-

Download Data